Insights from Patients and Physicians About Use of Evolocumab for LDL-C Management.

ABSTRACT:

Introduction

Low-density lipoprotein-cholesterol (LDL-C) is a causal modifiable risk factor for atherosclerotic cardiovascular disease (ASCVD), and evolocumab-a proprotein subtilisin/kexin type 9 (PCSK9) inhibitor monoclonal antibody-is effective in substantially decreasing LDL-C concentrations. However, many patients who might benefit from PCSK9 inhibitor treatment as per current guideline recommendations will not receive it. Our study aimed to assess patient and physician satisfaction with evolocumab, including perceptions of treatment experience and effectiveness.

Methods

The Treatment Satisfaction Questionnaire for Medication (TSQM)-9 (nine items; 7- or 5-point Likert scale responses) evaluated satisfaction in 130 adult patients (50% women) using evolocumab. A separate s

SUBMITTER: Sidelnikov E 

PROVIDER: S-EPMC12474688 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature